Evidence map›Paper›PMID 39351512›Full record

ArticleWorld journal of hepatology2024

Predictors of survival in autoimmune liver disease overlap syndromes.

Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, Malik Janjua, Bastiaan de Boer, John Joseph, Wendy Cheng, Simon Hazeldine, Briohny W Smith, Gerry C MacQuillan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Overlap syndromes in autoimmune liver disease: a review.Translational gastroenterology and hepatology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dujinthan JayabalanMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Yi HuangDepartment of Hepatology, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Luis Calzadilla-BertotMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Malik JanjuaDepartment of Hepatology, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Bastiaan de BoerDepartment of Anatomical Pathology, PathWest Laboratory Medicine, Nedlands 6009, Western Australia, Australia.
John JosephDepartment of Anatomical Pathology, PathWest Laboratory Medicine, Nedlands 6009, Western Australia, Australia.
Wendy ChengDepartment of Gastroenterology and Hepatology, Royal Perth Hospital, Perth 6000, Western Australia, Australia.
Simon HazeldineDepartment of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch 6150, Western Australia, Australia.
Briohny W SmithDepartment of Hepatology, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.
Gerry C MacQuillanMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Michael C WallaceMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
George GarasMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Leon A AdamsMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.
Gary P JeffreyMedical School, University of Western Australia, Nedlands 6009, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival in patients with autoimmune liver disease overlap syndromes (AILDOS) compared to those with single autoimmune liver disease is unclear.

aimTo investigate the survival of patients with AILDOS and assess the accuracy of non-invasive serum models for predicting liver-related death.

methodsPatients with AILDOS were defined as either autoimmune hepatitis and primary biliary cholangitis overlap (AIH-PBC) or autoimmune hepatitis and primary sclerosing cholangitis overlap (AIH-PSC) and were identified from three tertiary centres for this cohort study. Liver-related death or transplantation (liver-related mortality) was determined using a population-based data linkage system. Prognostic scores for liver-related death were compared for accuracy [including liver outcome score (LOS), Hepascore, Mayo Score, model for end-stage liver disease (MELD) score and MELD incorporated with serum sodium (MELD-Na) score].

resultsTwenty-two AILDOS patients were followed for a median of 3.1 years (range, 0.35-7.7). Fourteen were female, the median age was 46.7 years (range, 17.8 to 82.1) and median Hepascore was 1 (range, 0.07-1). At five years post enrolment, 57% of patients remained free from liver-related mortality (74% AIH-PBC, 27% AIH-PSC). There was no significant difference in survival between AIH-PBC and AIH-PSC. LOS was a significant predictor of liver-related mortality (

conclusionSurvival in the rare, AILDOS is unclear. The current study supports the LOS as a predictor of liver-related mortality in AIH-PBC patients. Further trials investigating predictors of survival in AILDOS are required.

Indexed as

Autoimmune hepatitisAutoimmune liver disease overlap syndromesHepascoreLiver outcome scoreLiver-related deathPrimary biliary cholangitisPrimary sclerosing cholangitis

Identifiers

PMID39351512
PMCPMC11438591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.